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Abstract
Background: Denosumab is a fully human monoclonal antibody that inhibits receptor activator of nuclear factor
kappa-β ligand (RANKL). Previous reports have shown that denosumab treatment of osteoporotic patients
decreases bone resorption and fracture risk, but there have been no clinical studies on changes in bone turnover
markers, 1,25(OH)2D3, or parathyroid hormone (PTH) in denosumab therapy with or without bisphosphonate (BP)
pre-treatment in Japan.
Methods: Here, we report such findings in 22 patients (11 in the denosumab alone group and 11 in the BP
pre-treated group) with osteoporosis following 4 months of treatment. Bone metabolism had been inhibited by
prior BP administration in the BP pre-treated group.
Results: The bone resorption markers serum tartrate-resistant acid phosphatase type 5b and urinary type I collagen
cross-linked N-telopeptide were significantly decreased from baseline values for the entire study period in both
groups. The bone formation marker bone alkaline phosphatase was significantly decreased at 4 months in the
denosumab alone group only, and N-terminal propeptide of type 1 procollagen was significantly decreased at 2
and 4 months in the denosumab alone group versus no remarkable change in the BP pre-treated group. In the
denosumab alone group, 1,25(OH)2D3 and PTH were significantly increased at 1 week and decreased gradually
thereafter, but these did not change notably in the BP pre-treated group.
Conclusions: Our results suggest that treatment with denosumab causes a strong inhibitory effect on bone
resorption markers and mild inhibitory effect on bone formation markers. 1,25(OH)2D3 and PTH were significantly
increased by denosumab but these did not change in the BP pre-treated group.
Trial registration: Current Controlled Trials NCT02156960. Registered 31 May 2014.
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Background
Osteoporosis is a major health concern, especially in elderly
women, that carries an increased incidence of bone fracture
and ensuing morbidity. Thus, the prevention of fractures is
the primary therapeutic goal for this condition [1].
Recent treatments for osteoporosis have been based on
our current understanding of bone biology. Receptor acti-
vator of nuclear factor-kB ligand (RANKL) is a cytokine
that is essential for osteoclast differentiation, activation,
and survival [2]. Denosumab, a fully human monoclonal
antibody against RANKL shown to selectively inhibit oste-
oclastogenesis, was approved for use in Japan in 2013. As
severe osteoporosis in RANKL transgenic mice was re-
versed by denosumab administration [3], RANKL appears
to be an ideal target for osteoporosis treatment.
In one report, denosumab therapy resulted in a signifi-
cant, early, and sustained increase in bone mineral density
(BMD) and enhanced bone strength in the improvement
of both cortical and trabecular bones [4]. Another review
described that denosumab treatment for 6 years main-
tained a low fracture incidence, reduced bone turnover,
and an increase in BMD [5]. There have been some re-
ports comparing bisphosphonate (BP) and denosumab
therapy after BP pre-treatment in osteoporosis [6–8],
wherein denosumab increased BMD and inhibited bone
resorptive markers more than BP treatment. In patients
previously treated with BP, denosumab treatment resulted
in higher BMD increases and greater decreases in bone re-
sorption markers than BP alone [6–9].
The major form of vitamin D in the serum is 25(OH)D,
which is its principal storage conformation whose concentra-
tion is approximately 1000 times higher than that of
1,25(OH)2D3. The status of vitamin D in the body is typically
evaluated using the stored form of serum 25(OH)D [10].
The 1,25(OH)2D3 form of vitamin D exerts various major
effects on vitamin D metabolism. 1,25[OH]2D3 is tightly
regulated by parathyroid hormone (PTH), fibroblast growth
factor (FGF)-23, and other hormones, as well as by cytokines
[11]. As it is generally considered that serum 1,25[OH]2D3
level is not altered in normal conditions, there have been no
reports on the regulation of serum 1,25[OH]2D3 and PTH
during osteoporosis treatment with denosumab.
While both are anti-resorptive drugs, BP and denosumab
have different action mechanisms in osteoporosis. BP func-
tions after bone deposition and has a long half-life and dur-
ation of anti-absorptive effects. Therefore, bone metabolism
may be affected by BP pre-treatment, although there have
been no reports on whether prior treatment with BP affects
serum PTH or vitamin D levels during treatment with
denosumab.
In this study, we examined the clinical results of
4 months of denosumab treatment with or without BP
pre-treatment on bone turnover markers, serum Ca,
1,25(OH)2D3, and PTH in Japanese osteoporotic patients.
Methods
Twenty-two patients with osteoporosis (16 women and 6
men) were recruited for this study at our institutions be-
tween July 2013 and April 2014. The cohort’s average age
was 74.6 years. The patients were divided into 2 groups of
11 patients each for the denosumab alone (7 women and
4 men; mean ± standard deviation (SD) age: 76.3 ±
7.0 years in women and 69.8 ± 9.2 years in men) and BP
pre-treated (2 men and 9 women; mean ± SD age: 75.9 ±
3.4 years in women and 69.0 ± 5.0 years in men) groups.
All patients were diagnosed as having primary osteopor-
osis. Patients in the denosumab alone group had no his-
tory of medication that may have affected bone or calcium
(Ca) metabolism, while those in the BP pre-treated group
had been taking oral BP for at least 6 months prior to this
study. The diagnosis of primary osteoporosis was made in
accordance with the revised criteria established by the Jap-
anese Society of Bone and Mineral Research [12]. We gave
daily Ca and vitamin D supplements to all patients during
the denosumab administration period.
Serum Ca was corrected with serum albumin (the refer-
ence range 8.5–10.2 mg/dL). Serum bone alkaline
phosphatase (BAP) (the reference range in postmenopausal
women 3.8–22.6 μg/L) and N-terminal propeptide of type 1
procollagen (P1NP) (the reference range in postmenopausal
women 27.0–109.3 ng/mL) were measured as bone forma-
tion markers using a chemiluminescent enzyme immuno-
assay and an antibody radioimmunoassay, respectively.
Serum tartrate-resistant acid phosphatase (TRACP)-5b (the
reference range in women 120–420 mU/dL) and urine
N-terminal telopeptide of type I collagen (NTX) (the refer-
ence range in postmenopausal women 14.3–89.0 nmolBCE/
mmol CRE) (Osteomark, Osteox International, Seattle,
WA) were measured as markers of bone resorption using
the enzyme-linked immunosorbent assay (ELISA). Serum
whole PTH (9–39 pg/mL) and 1,25(OH)2D3 (20.0–60.0
pg/mL) were measured by immunoradiometric assays. Each
marker was measured just prior to denosumab administration
and at 1 week, 1, 2, and 4 months of denosumab treatment.
After overnight fasting, serum and first void urine samples
were collected between 8:30 a.m. and 10:00 a.m. Immunoas-
says were performed by SRL, Inc. (Tokyo, Japan).
Bone mineral density (BMD) was measured using a Dual-
energy X-ray Absorption (DXA) fan-beam bone densitom-
eter (Lunar Prodigy; GE Healthcare Bio-Sciences Corp.,
Piscataway, NJ, USA) at the L1-4 levels of the postero-
anterior spine and bilateral hips.
In both groups, we compared the changes in each
marker at each time point (at first administration of
denosumab and at 1 week, 1, 2, and 4 months after-
wards) using linear mixed models and Holm’s correction
method for multiple comparisons. Each marker value
was individually adopted as a response variable: the tim-
ing of the measurement was used as a fixed effect, while
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the individuality of the measurement was adopted as a
random effect. Comparisons between the markers of
both groups at each measuring point were performed
using Welch’s t-test. P-values of < 0.05 were considered
to be statistically significant. Statistical analyses were
performed using the statistical package R, version 3.0.1
(R Development Core Team, http://www.r-project.org).
The authors received no hospitality, honoraria, or
travel expenses via the companies that market deno-
sumab. This study was approved by the institutional
ethical review board at Shinshu University School of
Medicine and Show Inan General Hospital prior to its
start and written informed consent was obtained from
all subjects.
Results
Serum corrected calcium level
Serum Ca level did not change significantly in either
group. The changes in adjusted Ca were within the ref-
erence range. However, whereas Ca was decreased at
1 week and 1 month before returning to baseline levels
at 2 months in the denosumab alone group, it was in-
creased in the BP pre-treatment group at 1 week and
1 month (Fig. 1a).
Bone turnover markers
Bone resorption markers
Serum TRACP-5b and urinary NTX were significantly
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Fig. 1 Low Ca stimulates PTH and 1,25(OH)2D3 expression. a Serum Ca in the denosumab alone group did not show any significant changes, but
was decreased at 1 week and 1 month followed by a return to baseline levels at 4 months. In the BP pre-treated group, Ca was increased at
1 week and 1 month and gradually decreased thereafter. Group comparisons showed no significant differences at any time point. Straight line:
Pre-treated BP group, dotted line: Denosumab alone group. b In the denosumab alone group, serum 1,25(OH)2D3 was significantly increased from
1 week to 2 months, and then gradually decreased thereafter. In the BP pre-treated group, serum 1,25(OH)2D3 did not significantly change during
the study period. Group comparisons showed significant differences from 1 week to 4 months. Straight line: Pre-treated BP group, dotted line:
Denosumab alone group. Asterisks indicate significant differences. c In the denosumab alone group, whole PTH was significantly increased at
1 week, and then gradually decreased thereafter. In the BP pre-treated group, PTH did not significantly change during the study period. Group
comparisons showed significant differences at 1 week and 1 month. Straight line: Pre-treated BP group, dotted line: Denosumab alone group.
Asterisks indicate significant differences
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administration. However, the resorption markers were
nonetheless significantly inhibited by denosumab at each
time point in both groups (Fig. 2a and b). In the groups,
serum TRACP-5b and urinary NTX were significantly
inhibited from as early as 1 week to 4 months. These re-
sults indicated an immediate and strong anti-resorptive
effect of denosumab, even in the BP pre-treated group
(Fig. 2a and b).
Bone formation markers
Similarly to bone resorption markers, in the BP pre-treated
group, BAP and P1NP were at notably lower values com-
pared with the denosumab alone group at treatment onset.
In the denosumab alone group, BAP rose slightly at
1 month but then gradually decreased until 4 months after
initiation of treatment to a significant degree. P1NP was
markedly decreased at 1 week and became significantly
lower at 2 and 4 months (Fig. 2c). In the BP pre-treatment
group, these bone formation markers had decreased slightly
by the end of the observation period (Fig. 2c and d). The
values of BAP at 1 month and P1NP at 1 week to 4 months
were significantly higher in the denosumab alone group
(Fig. 2c and d). These results indicated that following pre-
BP treatment, the inhibitory effects on bone formation
markers by denosumab were much less pronounced than
those in the denosumab alone group.
Fig. 2 Bone absorption markers were significantly inhibited in the early stages of denosumab administration, whereas bone formation markers
were gradually inhibited by denosumab. a In the denosumab alone group, serum TRACP-5b was significantly inhibited from 1 week to 4 months.
TRACP-5b reached its minimum value at 1 month. In the BP pre-treated group, TRACP-5b was also significantly inhibited from 1 week to 4 months,
albeit less than in the denosumab alone group. Group comparisons showed significant differences before administration and at 1 week of
administration. Straight line: Pre-treated BP group, dotted line: Denosumab alone group. Asterisks indicate significant differences. b In the
denosumab alone group, urinary NTX was significantly inhibited from 1 week to 4 months. Urinary NTX reached its minimum value at 2 months. In
the BP pre-treated group, urinary NTX was also significantly inhibited from 1 week to 4 months, albeit less than in the denosumab alone group. Group
comparisons showed a significant difference before administration. Straight line: Pre-treated BP group, dotted line: Denosumab alone group. Asterisks
indicate significant differences. c In the denosumab alone group, BAP peaked at 1 month, but then decreased to a significant value at 4 months. In
the BP pre-treated group, BAP did not change significantly during the observation period. Group comparisons showed a significant difference at
1 month. Straight line: Pre-treated BP group, dotted line: Denosumab alone group. Asterisks indicate significant differences. d In the denosumab alone
group, P1NP was significantly decreased at 2 and 4 months. In the BP pre-treated group, P1NP did not change significantly during the observation
period. Group comparisons showed significant differences from 1 week to 4 months. Straight line: Pre-treated BP group, dotted line: Denosumab alone
group. Asterisks indicate significant differences
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Serum 1,25(OH)2D3 and whole parathyroid hormone
(PTH)
In the denosumab alone group, serum 1,25(OH)2D3 was
significantly increased from as early as 1 week to
2 months, peaked at 1 week after denosumab adminis-
tration, and then gradually decreased. Similarly, whole
PTH was significantly increased at 1 week and slowly
decreased thereafter (Fig. 1b and c).
In the BP pre-treated group, serum 1,25(OH)2D3 level
was increased slightly up to 4 months. Whole PTH level
did not increase, and in fact decreased slightly, but not
significantly, during the observation period (Fig. 1b and c).
Before denosumab administration, there were no signifi-
cant differences in baseline levels of 1,25(OH)2D3 or
whole PTH between groups. However, values of
1,25(OH)2D3 at 1 week to 4 months and whole PTH at
1 week and 1 month became significantly higher in the
denosumab alone group than in BP pre-treated group
(Fig. 1b and c).
Discussion
In the present study, denosumab administration in the
denosumab alone group caused: 1) strong inhibitory ef-
fects on bone resorption from as early as 1 week, 2) a
slight decrease in Ca at 1 week and 1 month and a sig-
nificant increase in 1,25(OH)2D3 and PTH at 1 week,
followed by a gradual decrease, and 3) mild inhibitory ef-
fects on bone formation markers during the observation
period. On the other hand, in the BP pre-treated group,
denosumab administration resulted in: 1) further signifi-
cant inhibition of urinary NTX and serum TRACP-5b,
2) a slight decrease in BAP and P1NP, 3) a slight in-
crease in Ca at 1 week and 1 month, and 4) no marked
changes in 1,25(OH)2D3 or PTH.
We noted that the bone resorption markers serum
TRACP-5b and urinary NTX were significantly lower in
the BP pre-treatment group at study onset, which indi-
cated that prior therapy with BP had effectively modu-
lated bone resorption. However, these markers
decreased significantly from as early as 1 week and lev-
eled off at 1 week for urinary NTX and 1 month for
TRACP-5b. Hence, denosumab has strong inhibitory ef-
fects on bone resorption at an early stage after therapy
commencement, regardless of BP pre-treatment.
With respect to bone formation markers, both BAP
and P1NP also showed lower, albeit insignificant, values
in the BP pre-treated group. In the denosumab alone
group, BAP decreased steadily and P1NP decreased
slowly after an initial marked drop. At 4 months, both
values had decreased to comparable levels in both
groups. However, P1NP at 4 months remained signifi-
cantly higher in the denosmub alone group. In the BP
pre-treated group, the values of serum BP and P1NP de-
creased slightly.
Generally, bone resorption and bone formation change
in parallel due to the phenomenon of coupling [13].
However, we observed that this was not the case for
denosumab; regardless of previous BP treatment, bone
resorption was strongly inhibited in the early stages of
drug administration. In the BP pre-treated group, the in-
hibitory effects on bone formation markers by denosu-
mab were not obviously evident.
Ca status is strictly regulated by intestinal Ca absorption,
bone resorption, and renal re-absorption. 1,25(OH)2D3 in-
creases intestinal Ca absorption and resorption of Ca from
bone, and therefore plays a prominent role in Ca regula-
tion along with PTH [13, 14]. PTH also increases bone re-
sorption and the production of 1,25(OH)2D3 [14]. Ca
absorption occurs through changes in the level of
1,25(OH)2D3 that must be synthesized de novo in response
to PTH [14]. As the half life of 1,25(OH)2D3 is compara-
tively short, the regulation of Ca, PTH, and 1,25(OH)2D3
levels is usually strictly regulated in the body.
Shiraki et al. have reported that serum 1,25(OH)2D3
and PTH levels transiently increased after alendonate ad-
ministration by a yet unknown mechanism [15]. We spec-
ulated that the reasons for the changes in 1,25(OH)2D3
and PTH caused by BP therapy were decreased Ca. Fur-
thermore, increased 1-25(OH)2D3 caused: 1) PTH recep-
tor increase [16], 2) accelerated PTH action, 3) further
increase in Ca, and 4) subsequent decreased PTH and
1,25(OH)2D3 levels [15]. In our study, in the denosumab
alone group, 1,25(OH)2D3 and PTH also significantly in-
creased after denosumab treatment. It is conceivable that
a similar mechanism is involved by which denosumab
strongly inhibits bone resorption, resulting in immediate
and significant 1,25(OH)2D3 and PTH increases.
The most important finding in this study was that in
the BP pre-treated group, regardless of further inhibiton
of bone resorptive markers by denosumab therapy,
1,25(OH)2D3 did not increase and PTH tended to de-
crease. However, the mechanisms for such phenomena
remain unknown.
The limitations of this study are 1) a small sample size,
2) short follow-up period, and 3) only a tendency of
serum Ca changes may have been demonstrated due to
the small cohort.
Conclusion
In conclusion, denosumab has a strong inhibitory effect
on bone resorption markers, although its inhibitory
effects on bone formation markers are weak. Levels of
1,25(OH)2D3 and PTH were temporarily increased by
denosumab treatment in the denosumab alone group.
On the other hand, the values of these parameters did
not change further as bone absorptive markers became
significantly inhibited in the BP pre-treated group.
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